AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys
about
A review of the use of zonisamide in Parkinson's diseaseStriatal glutamate release in L-DOPA-induced dyskinetic animalsPost- versus presynaptic plasticity in L-DOPA-induced dyskinesia.Maladaptive striatal plasticity in L-DOPA-induced dyskinesia.Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study.Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys.The fluctuating Parkinsonian patient--clinical and pathophysiological aspects.Glutamatergic pathways as a target for the treatment of dyskinesias in Parkinson's disease.Striatal glutamatergic mechanisms and extrapyramidal movement disorders.L-DOPA-Induced Dyskinesia and Abnormal Signaling in Striatal Medium Spiny Neurons: Focus on Dopamine D1 Receptor-Mediated Transmission.Anatomy of Graft-induced Dyskinesias: Circuit Remodeling in the Parkinsonian StriatumNovel pharmacological strategies for motor complications in Parkinson's disease.Nondopaminergic mechanisms in levodopa-induced dyskinesia.The Antiparkinsonian and Antidyskinetic Mechanisms of Mucuna pruriens in the MPTP-Treated Nonhuman Primate.Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure.Levodopa, motor fluctuations and dyskinesia in Parkinson's disease.Emerging drugs for Parkinson's disease.An update on pharmacological approaches to neurodegenerative diseases.Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment.Gene transfer of constitutively active protein kinase C into striatal neurons accelerates onset of levodopa-induced motor response alterations in parkinsonian rats.Parkinson's disease: levodopa-induced dyskinesia and signal transduction.Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities.Treatment of levodopa-induced motor complications.Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline?Glutamate receptors as therapeutic targets for Parkinson's disease.Amphetamine stimulates movement through thalamocortical glutamate release.The AMPA receptor as a therapeutic target: current perspectives and emerging possibilities.Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.New pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors.Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.Some molecular mechanisms of dopaminergic and glutamatergic dysfunctioning in Parkinson's disease.The adverse event profile of perampanel: meta-analysis of randomized controlled trials.AMPA receptor inhibitors for the treatment of epilepsy: the role of perampanel.Levodopa-induced dyskinesias in Parkinson's disease: emerging treatmentsTherapeutic potential of targeting glutamate receptors in Parkinson's disease.Advances in non-dopaminergic treatments for Parkinson's diseasePharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.Nondopaminergic treatments for Parkinson's disease: current and future prospects.
P2860
Q28301683-23A22DB4-5183-4074-9659-F0BBDA99A499Q28485942-D9A0F38B-E286-4025-A8F3-671C2E640078Q33255884-23247A2C-D0BE-4074-B08A-B51E978198BFQ34094008-4181113F-E25A-41E5-8B40-4BC21AD8BB16Q34325365-01892663-E3D6-4028-8971-A9831519A397Q34532735-B0842ACD-63E9-4843-820B-99ABD85A32A9Q34619534-822ADBE6-6E25-4029-A7E5-FE46B930B8EFQ35065682-9A04A9FC-9733-4269-A95A-87034C1CEAA1Q35105740-547DA299-C997-4403-94CE-C65EE34024A2Q35124773-74539557-55DC-4B36-AA98-5143BF71C38FQ35165439-AA418FCA-B0FE-4F52-A819-8F534464C6B2Q35424424-FFD3CBD1-F350-4DDB-A336-4721010C418AQ36034592-0DBC9D3E-034D-43D8-BBFE-E96A299B6C86Q36120761-5CEBFAD6-142B-41D8-800F-EBAF9F151894Q36188913-D069916A-E1A9-4319-B599-226B98198E2CQ36241835-D086EEB2-EB25-4C1F-B9E2-84C906DD9B4EQ36549794-265C3338-305E-4E3A-9E2A-925B5472FDF1Q36573882-9A7C4537-EE3B-498E-A1E2-89AF1AC0FE41Q36580572-2A24402F-4DFF-4C40-928A-EF1B3B557272Q36677402-98C5C088-F9B8-4E8C-9045-F230C1B86736Q36873506-48B58C5A-FAEA-4F2B-B7A8-62FEAC0C7EB4Q36969324-BA84FCC0-2581-4DAC-8745-1757D7CFB187Q37086131-2039240D-4F34-43EE-AC30-9073F4684250Q37264464-E6953A34-67B9-4B39-BA10-C56A769A0A3BQ37264482-FB448228-28C6-4C38-9E58-2CC6380AA530Q37506507-1C3255B4-C601-4CF3-8B55-BF42D011F92BQ37585401-DB82821E-7E63-4E3C-90B6-04B4519A0DEAQ37598685-99D1F4AD-861D-464A-BDA1-07C47D187611Q37855933-72F449C4-E197-4175-9571-666C66AF542BQ37924629-D96DCFBA-08A0-4EAC-B298-7A5B050BC125Q37974709-1C9FF4D8-1A62-4F74-881C-F9C3A1D1071CQ38056852-FC4668A1-432B-4B9C-9A7B-8059BACFEA5DQ38063779-52C8218D-D200-4652-9961-0EF7C2B99FB9Q38100835-3FA15930-1BA8-41E1-9297-9170F73291DBQ38112213-5E8EC75B-74EA-4FAD-A330-91CD4C3D2937Q38156760-5FDC31D1-0630-41F6-9987-F3D710BC7F9EQ38190016-9506E3F2-469D-44A2-8626-861CE8E9B76DQ38218083-247CDE78-7E18-4318-85E3-D399C40CA6EAQ38262418-C205191A-E464-48EF-8357-7A0514ECB1DDQ38845546-CD1DA8B8-CA17-4FBA-BC42-75F10221B91D
P2860
AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys
@ast
AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys
@en
AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys
@nl
type
label
AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys
@ast
AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys
@en
AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys
@nl
prefLabel
AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys
@ast
AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys
@en
AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys
@nl
P2093
P356
P1433
P1476
AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys
@en
P2093
L Verhagen
P J Blanchet
S Konitsiotis
P304
P356
10.1212/WNL.54.8.1589
P407
P577
2000-04-25T00:00:00Z